Charles River Laboratories

The U.S. Senate on Dec. 16 passed the FDA Modernization Act 3.0 (S.355) by unanimous consent, sending legislation to the House that would require the FDA to update its regulations to reflect changes Congress enacted in 2022. The bill instructs HHS, acting through the FDA commissioner, to publish an interim final rule no later than…

In recent years, the cell and gene therapy market has grown at a rapid clip. The momentum is likely to continue. According to Vision Research Reports, the global cell and gene therapy market size could hit around $42.56 billion by 2030, growing at a CAGR of 39% from 2022 to 2030. The burgeoning demand in…

Charles River Laboratories (NYSE:CRL) announced that it completed a $292.5 million acquisition of Vigene Biosciences. Rockville, Md.-based Vigene, a gene therapy contract development and manufacturing organization (CDMO), develops viral vector-based gene delivery systems, with a primary area of expertise in CGMP viral vector manufacturing for gene therapies and gene-modified cell therapies. Get the full story…